Description of the medicine: Phenyl salicylate (Phenylii salicylas)
Phenylsalicylate (Phenylii salicylas).
Phenyl ester of salicylic acid.
Synonyms: Salol, Phenylium salicylicum, Salolum.
White crystalline powder or small, colorless crystals with a faint odor. It is practically insoluble in water, soluble (1:10) in alcohol, caustic alkali solutions.
Phenyl salicylate (salol) was synthesized a long time ago (1886, L. Nentsky) with the aim of creating a drug that would not break down in the acidic contents of the stomach and would not act irritantly on the gastric mucosa, but break down in the alkaline contents of the intestine and release salicylic acid and phenol. Phenol would have an inhibitory effect on the pathogenic intestinal microflora, salicylic acid would have some antipyretic and anti-inflammatory effect, and both compounds, partially excreted by the kidneys, would disinfect the urinary tract.
This principle (the "salting" principle - the Nentsky principle) was essentially one of the first experiments to create prodrugs (prodrug) (see also Hexamethylenetetramine).
For a long time, phenyl salicylate was widely used for intestinal diseases (colitis, enterocolitis), for cystitis, pyelitis, pyelonephritis.
Compared with modern antibacterial drugs: antibiotics, sulfonamides, fluoroquinolones, etc. - phenyl salicylate is much less active. However, it has low toxicity, does not cause dysbiosis and other complications, and therefore continues to be sometimes used in outpatient practice (often in combination with other drugs) for mild forms of these diseases. With more severe forms of diseases, it is necessary to use more active drugs.
Phenyl salicylate is prescribed orally at 0.25-0.5 g per reception 3-4 times a day, often in combination with antispasmodic astringents and other agents.
Release form: powder, tablets of 0.25 and 0.5 g and various combination tablets: a) tablets <Besalol> (Tabulettae <Besalolum>); composition: phenyl salicylate 0.3 g, belladonna extract 0.01 g; b) tablets <Urobesal> (Tabulettae <<Urobesalum>>); composition: phenyl salicylate and heximethylenetetramine 0.25 g each, belladonna extract 0.015 g; c) tablets <Tansal >> (Tabulettae <Tansalum>); composition: phenyl salicylate and tanalbine 0.3 g each; g) phenyl salicylate and bismuth basic nitrate 0.25 g each, belladonna extract 0.015 g.
Fencortosol (Phencortosolum). Contains phenyl salicylate and hydrocortisone acetate. It is used as a photoprotective and anti-inflammatory agent for photodermatosis, discoid lupus erythematosus. The course of treatment is 7 to 10 days. If necessary, repeat the treatment after 5 to 7 days.
Release form: emulsion in aerosol cans with a capacity of 55 g.
When the cylinder valve is pressed for 1–2 s, 7–14 cm of foam (0.7–1.4 g of foam) comes out, sufficient to cover 500 from the skin surface. At the same time, up to 30 cm 'of foam can be applied to the skin. The foam is rubbed evenly into the skin with massaging movements.
Do not use the drug on sunny days of the cold season.
Storage: at a temperature not exceeding 40 C.